Remove Hospital Remove Quality of Life Remove Transplant
article thumbnail

CareDx Launches Two Expanded Indications for AlloSure Testing Services

DAIC

The Transplant Company recently announced that AlloSureis now commercially available for pediatric heart transplant patients of all ages and patients who have received a simultaneous pancreas-kidney (SPK) transplant. 1 "The availability of AlloSure dd-cfDNA for all pediatric heart transplant patients is a major development.

article thumbnail

Ochsner Children’s Hospital Advocates to Close the Gap in Pediatric Heart Care

DAIC

Getty Images milla1cf Wed, 02/21/2024 - 19:10 February 21, 2024 — Ochsner Children's Hospital , ranked among the top hospitals in the nation for pediatric cardiology and congenital heart surgery, is raising awareness of the need for more pediatric-specific heart devices. Yet, research and innovation in this field has not kept pace.

article thumbnail

Congenital Heart Defects: Helping Families Navigate the Challenges

MIBHS

Heart Transplant : In the most severe cases, where the heart is too damaged to be repaired, a heart transplant may be necessary. Hospital stays, surgeries, medications, and ongoing treatments can add up quickly. This involves opening the chest and heart to make the necessary repairs.

article thumbnail

CVRx Announces Availability of Additional Data Supporting Long-term Benefits of Barostim

DAIC

William Abraham of the Ohio State Wexner College of Medicine presented analysis showing that patients in the trial with Barostim + GDMT had a 74% reduced risk of receiving advanced heart failure interventions (transplant, LVAD, CCM, CRT or CardioMEMS) at long-term follow-up versus patients on GDMT alone. See more details at TCTMD.

article thumbnail

V-Wave to Present Late-Breaking Data from Pivotal RELIEVE-HF Study at American College of Cardiology Annual Scientific Session and Expo

DAIC

"We're pleased to present the RELIEVE-HF data at this year's ACC meeting, as we continue to advance this important technology with the goal of bringing a much-needed treatment option to patients with advanced heart failure, a leading cause of death and hospitalization in the U.S. and worldwide," said Neal Eigler, M.D. , CEO of V-Wave.

article thumbnail

RELIEVE-HF Trial Outcomes Reported at ACC.24 Find Impact of Interatrial Shunt May Vary by Heart Failure Type

DAIC

High left atrial pressure is a primary cause of shortness of breath and hospitalizations related to heart failure. It is designed to form a small connection or passage between the left and right atria to allow blood to leave the left atrium—especially as left atrial pressure rises—thus reducing the pressure in the left atrium and the lungs.

article thumbnail

Impact of Interatrial Shunt May Vary by Heart Failure Type

DAIC

High left atrial pressure is a primary cause of shortness of breath and hospitalizations related to heart failure. It is designed to form a small connection or passage between the left and right atria to allow blood to leave the left atrium—especially as left atrial pressure rises—thus reducing the pressure in the left atrium and the lungs.